Provided by Tiger Fintech (Singapore) Pte. Ltd.

ASCLETIS-B

7.650
-0.070-0.91%
Volume:5.47M
Turnover:41.23M
Market Cap:7.37B
PE:-23.32
High:7.790
Open:7.380
Low:7.220
Close:7.720
Loading ...

Company Profile

Company Name:
ASCLETIS-B
Exchange:
SEHK
Establishment Date:
2013
Employees:
231
Office Location:
12/F, Building D,198 Qidi Road, HIPARK,Xiaoshan District,Hangzhou,Zhejiang Province,China
Zip Code:
311200
Fax:
86 571 8538 9730
Introduction:
Ascletis Pharma Inc is an investment holding company mainly engaged in the research and development, production, and sales of pharmaceutical products. The Company focuses on viral diseases, non-alcoholic steatohepatitis (NASH) or primary biliary cholangitis (PBC), and oncology. The company's product pipeline includes ASC22 for chronic hepatitis B functional cure, ASC10 for respiratory syncytial virus (RSV), ASC22 for human immunodeficiency virus (HIV) functional cure, ASC10 and ASC11 for COVID-19, ASC41 for NASH, ASC42 for PBC, ASC61 for solid tumors, ASC40 for moderate and severe acne, and others.

Directors

Name
Position
WU Jin Zi
Chairman of the Board,Executive Director,Chairman of the Nomination Committee
HE Jing Dao
Executive Director,Member of the Remuneration and Assessment Committee
WEI Yi Zhen
Independent Director,Member of the Remuneration and Assessment Committee,Member of the Nomination Committee,Audit Committee Member
GU Jiong
Independent Director,Audit Committee Chairman
HUA Lin
Independent Director,Chairman of the Remuneration and Assessment Committee,Member of the Nomination Committee,Audit Committee Member

Shareholders

Name
Position
WU Jin Zi
CEO
ZHONG Ming Hui
Corporate Secretary
John P. GARGIULO
Chief Business Officer
YAN Yue Mei
Other Senior Executives,Other Senior Executives
HE Jing Dao
Other Senior Executives